Who is sponsoring NCT02764697?

NCT02764697 is sponsored by Tampa Bay Uveitis Center, LLC.

What condition does NCT02764697 study?

NCT02764697 studies Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema.

What drugs are being tested in NCT02764697?

Interventions: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION.

What is the status of NCT02764697?

NCT02764697 is currently COMPLETED.

Last reviewed 2018-07-02 · How we verify

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697 PHASE4 COMPLETED Results posted

Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. This inflammation, is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.

Details

Lead sponsor	Tampa Bay Uveitis Center, LLC
Phase	PHASE4
Status	COMPLETED
Enrolment	6
Start date	Thu Jun 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Uveitis
Anterior Uveitis
Intermediate Uveitis
Posterior Uveitis
Scleritis
Clinically Significant Macular Edema

Interventions

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION

Countries

United States